Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of BioAtla Inc (NASDAQ: BCAB) closed at $0.48 in the last session, down -8.19% from day before closing price of $0.52. In other words, the price has decreased by -$8.19 from its previous closing price. On the day, 0.68 million shares were traded.
Ratios:
We take a closer look at BCAB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.52 and its Current Ratio is at 3.52. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.00.
On September 15, 2022, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $17.
Credit Suisse Downgraded its Outperform to Neutral on May 05, 2022, whereas the target price for the stock was revised from $35 to $5.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.52 while its Price-to-Book (P/B) ratio in mrq is 1.94.
Stock Price History:
Over the past 52 weeks, BCAB has reached a high of $3.42, while it has fallen to a 52-week low of $0.24. The 50-Day Moving Average of the stock is 31.77%, while the 200-Day Moving Average is calculated to be -58.63%.
Shares Statistics:
A total of 58.10M shares are outstanding, with a floating share count of 45.38M. Insiders hold about 22.31% of the company’s shares, while institutions hold 38.40% stake in the company.
